These findings are in line with the observation that Melan-A/MART-1/HLA-A*0201 restricted peptide behaves as immune-dominant epitope in melanoma patients and a high proportion (about 70%) of advanced stage III-IV melanoma patients display a natural anti-Melan-A/MART-1 immunity [22]. Here, HLA-A is linked to melanoma.